Kirsten Achilles Poon

Statistics

Publications

Citations

808

H-Index

Active since

2010

Affiliations

Genesys (United States)(Current)

Impact Assessment

Ultragenyx Pharmaceutical (United States)

Leeds Teaching Hospitals NHS Trust

Bioanalytica (Switzerland)

Kirsten Achilles Poon is an author at Genesys (United States) specializing in antibody-drug conjugate therapy, antibody-drug conjugates, and pharmacy.

Publications per year

2010–2023

Publications

Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability

Kirsten Achilles Poon, Kelly M. Flagella, Joseph C. Beyer et al. · Toxicology and Applied Pharmacology · 2013 · 194 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

J.F. Liu, Kathleen N. Moore, Michael J. Birrer et al. · Annals of Oncology · 2016 · 140 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +12

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

Andrew G. Polson, Marna Williams, Aimee Gray et al. · Leukemia · 2010 · 88 citations

Pharmacy, Medicinal Chemistry, Oncology +14

DCDT2980S, an Anti-CD22-Monomethyl Auristatin E Antibody–Drug Conjugate, Is a Potential Treatment for Non-Hodgkin Lymphoma

Dongwei Li, Kirsten Achilles Poon, Shang‐Fan Yu et al. · Molecular Cancer Therapeutics · 2013 · 85 citations

Pharmacy, Oncology, Pharmacokinetics +17

Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers

Thomas H. Pillow, Melissa M. Schutten, Shang‐Fan Yu et al. · Molecular Cancer Therapeutics · 2017 · 69 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

1–5 of 11